Literature DB >> 23966748

A sudden total loss of vision after routine cataract surgery.

S Lartey1, P Armah, A Ampong.   

Abstract

We share our experience of a 50-year-old controlled hypertensive woman who had routine cataract surgery in her left eye. She was given retrobulbar Xylocaine with adrenalin and postoperative gentamycin. She subsequently became blind in the operated eye after developing macular infarction by the first day post operative and optic atrophy by 2 months postoperative. This could have been caused by vascular occlusion in an already compromised artherosclerosed vessels. It could also have been due to gentamyin toxicity. Gentamycin injection given subconjunctivally is known to rarely result in severe retinal toxicity. This case illustrates that even though cataract surgery is considerd a simple routine procedure, and is performed in high volumes, it is not without its blinding complications. We recommend that the use of adrenaline in xylocaine should be used with caution in hypertensive patients and also the routine use of subconjunctival gentamycin injection after cataract surgery should be reviewed and other modes of endophthalmitis prophylaxis be considered.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23966748      PMCID: PMC3743107     

Source DB:  PubMed          Journal:  Ghana Med J        ISSN: 0016-9560


  13 in total

1.  Amikacin retinal toxicity.

Authors:  T L Jackson; T H Williamson
Journal:  Br J Ophthalmol       Date:  1999-10       Impact factor: 4.638

2.  Acute aminoglycoside retinal toxicity in vivo and in vitro.

Authors:  Heather A Hancock; Clyde Guidry; Russell W Read; Edgar L Ready; Timothy W Kraft
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-12       Impact factor: 4.799

3.  Ocular toxicity in cataract surgery because of inaccurate preparation and erroneous use of 50mg/ml intracameral cefuroxime.

Authors:  Pärssinen Olavi
Journal:  Acta Ophthalmol       Date:  2011-04-06       Impact factor: 3.761

4.  Aminoglycoside toxicity--a survey of retinal specialists. Implications for ocular use.

Authors:  P A Campochiaro; B P Conway
Journal:  Arch Ophthalmol       Date:  1991-07

Review 5.  Gentamicin and other antibiotic toxicitiy.

Authors:  T Thomas; D Galiani; R D Brod
Journal:  Ophthalmol Clin North Am       Date:  2001-12

6.  Spectrum of aetiological agents of postoperative endophthalmitis and antibiotic susceptibility of bacterial isolates.

Authors:  A R Anand; K L Therese; H N Madhavan
Journal:  Indian J Ophthalmol       Date:  2000-06       Impact factor: 1.848

7.  Nosocomial acute-onset postoperative endophthalmitis survey. A 10-year review of incidence and outcomes.

Authors:  T M Aaberg; H W Flynn; J Schiffman; J Newton
Journal:  Ophthalmology       Date:  1998-06       Impact factor: 12.079

8.  Treatment of postcataract extraction endophthalmitis: a summary of the results from the Endophthalmitis Vitrectomy Study.

Authors:  Bernard H Doft
Journal:  Arch Ophthalmol       Date:  2008-04

9.  Empiric treatment of endophthalmitis. Are aminoglycosides necessary?

Authors:  S P Donahue; R P Kowalski; A W Eller; J M DeVaro; B H Jewart
Journal:  Arch Ophthalmol       Date:  1994-01

10.  Gentamicin-induced macular infarction in transconjunctival sutureless 25-gauge vitrectomy.

Authors:  Nicola Cardascia; Francesco Boscia; Claudio Furino; Luigi Sborgia
Journal:  Int Ophthalmol       Date:  2007-10-16       Impact factor: 2.031

View more
  2 in total

1.  Macular ischemia after intravitreal amikacin on patient with intraocular foreign body.

Authors:  Arief Kartasasmita; Susi Mona; Erwin Iskandar; Iwan Sovani; Djonggi Panggabean
Journal:  GMS Ophthalmol Cases       Date:  2017-03-24

2.  Zebrafish (Danio rerio) Is an Economical and Efficient Animal Model for Screening Potential Anti-cataract Compounds.

Authors:  Chun-Fu Liu; Yen Ou-Yang; Ching-Ying Huang; Shih-Wei Jao; Yu-Kai Kuo; Hung-Chi Chen; Shu-Chun Cheng; Nan-Kai Wang; Lan-Hsin Chuang; Yau-Hung Chen; Wei-Yi Chen
Journal:  Transl Vis Sci Technol       Date:  2022-08-01       Impact factor: 3.048

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.